The long-term goal of the proposed project is to improve the treatment of alcohol abuse and dependence in patients with schizophrenia and schizoaffective disorder. Alcohol use disorders are common among patients with severe mental illness. It is estimated that there may be as many as 750,000 individuals in the United States with comorbid schizophrenia and alcohol disorders. Alcohol disorder comorbidity requires treatment because it is associated with adverse consequences such as increased rates of hospitalization. Yet, to date, there are no reports of controlled trials testing the efficacy of pharmacological treatments for alcohol abuse or dependence in this population. Naltrexone pharmacotherapy is an effective treatment for alcohol dependence, but it has not been systematically applied to the care of patients with schizophrenia.
The specific aims of this study are: To test the efficacy of naltrexone in reducing alcohol use among individuals with schizophrenia and schizoaffective disorder who also have alcohol abuse or dependence. We will test hypothesis 1: Naltrexone will be more effective than placebo in reducing alcohol use. Our primary outcome measure will be the number of drinking days over the course of the treatment trial. To test naltrexone's efficacy in reducing psychiatric symptom severity and medical utilization by reducing alcohol use. We will test hypothesis 2: Patients responding to naltrexone by reducing alcohol use will also show reductions in severity of psychiatric symptoms and utilization of inpatient and emergency psychiatric services. To determine the relationship between a) changes in alcohol use, and b) psychiatric symptom severity and inpatient and emergency service utilization. We will test hypothesis 3: Severity of psychiatric symptoms and amount of service utilization will correlate positively with alcohol use. The proposed research will study a cohort of 150 subjects in a double-blind, randomized, placebo-controlled trial of naltrexone using three times per week directly observed administration of medication. The study will be 6 months in duration, consisting of a 12-week course of naltrexone or placebo plus 3 monthly follow-up interviews after discontinuation of medication. Voucher incentives contingent on attendance will be provided to all subjects to ensure attendance for medication administration. Weekly motivational enhancement counseling sessions will also be provided to all subjects. Study outcomes will consist of self-report and biological measures of alcohol use as well as measures of psychiatric symptom severity and medical service utilization.

National Institute of Health (NIH)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Research Project (R01)
Project #
Application #
Study Section
Health Services Research Review Subcommittee (AA)
Program Officer
Roach, Deidra
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Upstate Medical University
Schools of Medicine
United States
Zip Code
Batki, Steven L (2015) What is the right pharmacotherapy for alcohol use disorder in patients with schizophrenia? J Clin Psychiatry 76:e1336-7
Meszaros, Zsuzsa Szombathyne; Abdul-Malak, Ynesse; Dimmock, Jacqueline A et al. (2013) Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. J Clin Psychopharmacol 33:243-7
Meszaros, Zsuzsa Szombathyne; Dimmock, Jacqueline A; Ploutz-Snyder, Robert et al. (2011) Accuracy of self-reported medical problems in patients with alcohol dependence and co-occurring schizophrenia or schizoaffective disorder. Schizophr Res 132:190-3
Meszaros, Zsuzsa Szombathyne; Dimmock, Jacqueline A; Ploutz-Snyder, Robert J et al. (2011) Predictors of smoking severity in patients with schizophrenia and alcohol use disorders. Am J Addict 20:462-7
Leontieva, Luba; Dimmock, Jacqueline; Cavallerano, Michelle et al. (2009) Patient and provider attitudes towards monitored naltrexone treatment of alcohol dependence in schizophrenia. Am J Drug Alcohol Abuse 35:273-8
Batki, Steven L; Meszaros, Zsuzsa S; Strutynski, Katherine et al. (2009) Medical comorbidity in patients with schizophrenia and alcohol dependence. Schizophr Res 107:139-46
Batki, Steven L; Leontieva, Luba; Dimmock, Jacqueline A et al. (2008) Negative symptoms are associated with less alcohol use, craving, and ""high"" in alcohol dependent patients with schizophrenia. Schizophr Res 105:201-7
Leontieva, Luba; Dimmock, Jacqueline A; Gately, Paul W et al. (2008) Voucher-based incentives for naltrexone treatment attendance in schizophrenia and alcohol use disorders. Psychiatr Serv 59:310-4
Carey, Kate B; Leontieva, Luba; Dimmock, Jacqueline et al. (2007) Adapting Motivational Interventions for Comorbid Schizophrenia and Alcohol Use Disorders. Clin Psychol (New York) 14:39-57
Batki, Steven L; Dimmock, Jacqueline A; Wade, Michael et al. (2007) Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. Am J Addict 16:253-9